Holos Life Sciences
Singapore based life science company focused on epigenetics.
| Date | Investors | Amount | Round |
|---|---|---|---|
$540k | Early VC | ||
| Total Funding | 000k | ||
Related Content
Holos Life Sciences, established in Singapore in 2016, is a life sciences company focused on commercializing epigenetic biomarkers for personalized health and wellness. The company was founded by Scott Callender and Matthew Dallimore. The venture's creation was a result of a partnership with Oxford Biodynamics (OBD), stemming from an investment Callender made in 2007 when OBD's principals spun out from Oxford University. This background in private equity and operational involvement in investments shaped the foundation of Holos.
The core of Holos Life Sciences' business is the discovery and development of biomarkers based on 3D genomics, also known as chromatin architecture. This field studies how the three-dimensional folding of DNA in a cell's nucleus regulates gene expression, providing insights long before physical abnormalities appear. The company utilizes EpiSwitch™, a patented and clinically validated technology platform licensed from its shareholder, Oxford Biodynamics Plc. This platform identifies chromosome conformation signatures (CCS), which are stable, binary epigenetic biomarkers with both predictive and prognostic value.
Holos applies the EpiSwitch™ platform to non-disease state problems, aiming to create biomarkers that facilitate non-pharmaceutical improvements in health, wellness, and performance for both humans and animals. The company is developing applications in diverse areas, including predicting outcomes from interventions like exercise, enhancing the performance of thoroughbred racehorses, and improving the diagnosis and prognosis of mild Traumatic Brain Injury. By analyzing how biological, environmental, and behavioral factors affect the epigenome, Holos aims to provide actionable, personal, and precise insights for the next generation of personalized healthcare.
Keywords: epigenetic biomarkers, 3D genomics, personalized health, chromosome conformation signatures, EpiSwitch, Oxford Biodynamics, life sciences, animal wellness, human performance, traumatic brain injury diagnosis, exercise physiology, preventative healthcare, non-pharmaceutical interventions, biomarker discovery, chromatin architecture, multi-omic data, predictive biomarkers, prognostic indicators, livestock health, pet health, sports science